Drug Trial Radar · NCT07293351
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
474
Planned (sponsor's estimate)
Start
Mar 26, 2026
Primary completion
Nov 28, 2029
Study completion Nov 26, 2031
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- Collaborators
- BioNTech SE
- First posted
- Dec 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with other agents in participants with advanced Renal Cell Carcinoma (RCC)
Conditions
- Advanced Renal Cell Carcinoma (RCC)
Interventions
PumitamigDrug
Specified dose on specified days
IpilimumabDrug
Specified dose on specified days
CabozantinibDrug
Specified dose on specified days
CasdatifanDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs)Time frame: Up to approximately 2 years from end of treatment
- Number of participants with serious adverse events (SAEs) (as per Common Terminology Criteria for Adverse Events v5 (CTCAE v5))Time frame: Up to approximately 2 years from end of treatment
- Number of participants with AEs meeting protocol-defined dose-limiting toxicity (DLT) criteriaTime frame: Up to day 21 from first dose
- Number of participants with AEs leading to discontinuationTime frame: Up to approximately 2 years from end of treatment
- Number of participants with AEs leading to deathTime frame: Up to approximately 2 years from end of treatment
- Objective response rate (ORR) (confirmed complete response (CR) or partial response (PR)) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per investigator assessmentTime frame: Up to approximately 2 years from end of treatment
Locations
95 sites in 20 countries. Site status is shown where the registry gives one.
Local Institution - 0178
Palo Alto, California · Not yet recruiting
Local Institution - 0117
New Haven, Connecticut · Not yet recruiting
Sibley Memorial Hospital
Washington D.C., District of Columbia · Recruiting
Local Institution - 0177
Miami, Florida · Not yet recruiting
Local Institution - 0126
Orlando, Florida · Not yet recruiting
Local Institution - 0170
Fort Wayne, Indiana · Not yet recruiting
University Of Iowa Hospitals And Clinics
Iowa City, Iowa · Recruiting
Johns Hopkins Hospital
Baltimore, Maryland · Recruiting
Local Institution - 0176
Big Rapids, Michigan · Not yet recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Local Institution - 0135
Cincinnati, Ohio · Not yet recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
MUSC Hollings Cancer Center
Charleston, South Carolina · Recruiting
Carolina Urologic Research Center, LLC
Myrtle Beach, South Carolina · Recruiting
Local Institution - 0158
Salt Lake City, Utah · Withdrawn
Local Institution - 0095
Seattle, Washington · Not yet recruiting
Instituto Medico Especializado Alexander Fleming
Buenos Aires, Argentina · Recruiting
Local Institution - 0156
Buenos Aires, Argentina · Not yet recruiting
Asociación de Beneficencia Hospital Sirio Libanés
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Recruiting
Macquarie University
North Ryde, New South Wales, Australia · Recruiting
GenesisCare St Leonards
St Leonards, New South Wales, Australia · Recruiting
Mater Misericordiae Limited
Brisbane, Queensland, Australia · Recruiting
Local Institution - 0011
Herston, Queensland, Australia · Not yet recruiting
Local Institution - 0004
Heidelberg, Victoria, Australia · Not yet recruiting
Cabrini Hospital - Malvern
Malvern, Victoria, Australia · Recruiting
Local Institution - 0007
Calgary, Alberta, Canada · Not yet recruiting
Local Institution - 0189
Edmonton, Alberta, Canada · Not yet recruiting
Local Institution - 0109
Montreal, Quebec, Canada · Withdrawn
Local Institution - 0009
Montreal, Quebec, Canada · Not yet recruiting
Local Institution - 0006
Québec, Quebec, Canada · Not yet recruiting
Pontificia Universidad Catolica de Chile (PUC)
Santiago, Chile · Recruiting
Local Institution - 0105
Santiago, Santiago Metropolitan, Chile · Not yet recruiting
Bradfordhill
Santiago, Santiago Metropolitan, Chile · Recruiting
Local Institution - 0144
Beijing, China · Not yet recruiting
Local Institution - 0143
Beijing, Beijing Municipality, China · Not yet recruiting
Local Institution - 0157
Beijing, Beijing Municipality, China · Not yet recruiting
Local Institution - 0182
Guangzhou, Guangdong, China · Not yet recruiting
Local Institution - 0145
Tianjin, Hebei, China · Not yet recruiting
Local Institution - 0187
Harbin, Heilongjiang, China · Not yet recruiting
Showing 40 of 95 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.